China · Delayed Price · Currency is CNY BGI Genomics Statistics
Total Valuation
BGI Genomics has a market cap or net worth of CNY 15.82 billion. The enterprise value is 13.17 billion.
| Market Cap | 15.82B |
| Enterprise Value | 13.17B |
Important Dates
The last earnings date was Saturday, April 25, 2026.
| Earnings Date | Apr 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BGI Genomics has 383.85 million shares outstanding. The number of shares has increased by 0.98% in one year.
| Current Share Class | 383.85M |
| Shares Outstanding | 383.85M |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | 13.46% |
| Float | 219.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.12 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 103.73 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -22.97 |
| EV / Sales | 3.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -36.99 |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.60 |
| Quick Ratio | 2.31 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.69 |
| Interest Coverage | -13.69 |
Financial Efficiency
Return on equity (ROE) is -6.67% and return on invested capital (ROIC) is -9.22%.
| Return on Equity (ROE) | -6.67% |
| Return on Assets (ROA) | -2.71% |
| Return on Invested Capital (ROIC) | -9.22% |
| Return on Capital Employed (ROCE) | -5.69% |
| Weighted Average Cost of Capital (WACC) | 8.83% |
| Revenue Per Employee | 1.07M |
| Profits Per Employee | -160,190 |
| Employee Count | 3,580 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 4.90 |
Taxes
In the past 12 months, BGI Genomics has paid 48.64 million in taxes.
| Income Tax | 48.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.97% in the last 52 weeks. The beta is 0.86, so BGI Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -14.97% |
| 50-Day Moving Average | 42.97 |
| 200-Day Moving Average | 48.07 |
| Relative Strength Index (RSI) | 48.24 |
| Average Volume (20 Days) | 4,922,936 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BGI Genomics had revenue of CNY 3.84 billion and -573.48 million in losses. Loss per share was -1.37.
| Revenue | 3.84B |
| Gross Profit | 1.30B |
| Operating Income | -518.30M |
| Pretax Income | -543.80M |
| Net Income | -573.48M |
| EBITDA | -53.29M |
| EBIT | -518.30M |
| Loss Per Share | -1.37 |
Balance Sheet
The company has 3.36 billion in cash and 603.48 million in debt, with a net cash position of 2.76 billion or 7.19 per share.
| Cash & Cash Equivalents | 3.36B |
| Total Debt | 603.48M |
| Net Cash | 2.76B |
| Net Cash Per Share | 7.19 |
| Equity (Book Value) | 8.54B |
| Book Value Per Share | 20.27 |
| Working Capital | 3.57B |
Cash Flow
In the last 12 months, operating cash flow was 152.53 million and capital expenditures -508.64 million, giving a free cash flow of -356.11 million.
| Operating Cash Flow | 152.53M |
| Capital Expenditures | -508.64M |
| Depreciation & Amortization | 465.01M |
| Net Borrowing | -494.33M |
| Free Cash Flow | -356.11M |
| FCF Per Share | -0.93 |
Margins
Gross margin is 33.79%, with operating and profit margins of -13.49% and -14.93%.
| Gross Margin | 33.79% |
| Operating Margin | -13.49% |
| Pretax Margin | -14.15% |
| Profit Margin | -14.93% |
| EBITDA Margin | -1.39% |
| EBIT Margin | -13.49% |
| FCF Margin | n/a |
Dividends & Yields
BGI Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.98% |
| Shareholder Yield | -0.98% |
| Earnings Yield | -3.62% |
| FCF Yield | -2.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BGI Genomics has an Altman Z-Score of 5.01 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.01 |
| Piotroski F-Score | 4 |